



## **MedCU Receives FDA Marketing Clearance**

TEL AVIV, Israel, November 24<sup>th</sup>, 2018, Biotechnology company MedCu reported today that it has received FDA Marketing Clearance 510(k) to market its antibacterial wound dressings, designed to address a wide variety of acute, critical and chronic wounds.

The company's innovative wound dressing products are impregnated with copper particles. This implementation has been proven effective against a broad spectrum of bacteria, including those which are traditionally antibiotic resistant.

Current market research estimates the annual global wound dressing market at approximately \$8Bn and growing 6% Year over Year. This growth is the result of a constant increase in the prevalence of disease associated with obesity (diabetes), infectious diseases (bedsores, ulcers and burns) and the rise in the overall Life Expectancy.

The challenge of reducing and treating infections is of high priority to the global health market as innovative prevention and treatment solutions hold significant cost savings to the health system.

"This is a breakthrough in the wound dressing market," said Danny Lustiger, Co-founder and CEO of MedCU. "By leveraging the unique antibacterial properties of copper, we were able to develop an innovative product at a competitive price. The patent protected technology will change the standard dressing procedure and will significantly improve patient's welfare."

MedCU was founded by Biomed entrepreneurs Danny Lustiger and Dr Gadi Borkow.

Contact: Danny Lustiger, CEO [dannyl@medcu.com](mailto:dannyl@medcu.com)